1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

SSZSE:002262
21.67
CNY
+0.29
(+1.36%)
1.08EPS
17.39P/E
19.05BMarket Cap
Mar 25Next Earn
Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A
SZSE:002262
(Shenzhen Stock Exchange)

Recent

price

21.67

P/E

ratio

17.39

div

yld

1.67%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.48
1.81
2.02
2.28
2.55
2.74
2.99
3.36
3.82
4.13
3.32
3.9
4.25
5.01
5.63
5.87
6.08
Revenue per Share
0.09
0.12
0.14
0.18
0.23
0.26
0.31
0.39
0.52
0.66
0.72
0.79
0.89
1.03
1.13
1.05
1.08
Basic EPS, GAAP
-0.03
0.04
0.08
0.09
-0.1
-0.01
0.17
0.28
0.23
0.14
0.97
0.49
0.53
0.63
0.46
0.64
- -
Free Cash Flow per Basic Share
0.02
0.03
0.03
0.04
0.04
0.04
0.04
0.05
0.06
0.08
0.1
0.1
0.2
0.2
0.32
0.36
0.36
Dividend per Share
0.52
0.63
0.78
0.85
1.06
1.8
2.08
2.43
2.9
3.55
4.09
4.88
5.58
6.39
7.18
7.93
8.26
Book Value per Share
0.48
0.59
0.74
0.79
0.98
1.72
2
2.36
2.79
3.45
3.97
4.72
5.36
6.11
6.8
7.38
7.66
Tangible Book Value per Share
876
876
981
981
981
1,009
1,009
1,009
1,009
1,005
1,012
1,010
1,012
1,007
1,012
1,007
1,013
Basic Weighted Avg Shares
1,301
1,587
1,982
2,236
2,501
2,767
3,018
3,394
3,858
4,149
3,361
3,936
4,299
5,042
5,698
5,911
6,158
Sales/Revenue/Turnover
7.34
8.23
9
10.2
11.51
11.66
12.13
13.61
16.25
17.92
24.77
23.44
22.47
23.01
23.29
19.63
20.25
Operating Margin (%)
22
28
32
37
44
50
51
78
80
88
97
135
149
164
182
198
- -
Depreciation Expense
76
106
140
176
223
258
310
395
525
663
729
798
901
1,037
1,144
1,057
1,092
Net Income, GAAP
16.7
12.92
16.64
16
15.2
15.18
15.85
15.72
14.64
14.34
14.51
12.86
11.09
11.5
12.02
10.07
11.91
Effective Tax Rate (%)
5.88
6.65
7.05
7.88
8.93
9.34
10.26
11.63
13.6
15.99
21.68
20.27
20.95
20.57
20.07
17.89
17.73
Profit Margin (%)
172
247
358
450
410
1,005
1,201
1,516
1,928
2,488
2,726
3,361
3,856
4,441
4,993
5,371
5,653
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
46
48
42
36
34
20
15
LT Debt
463
556
682
836
1,059
1,827
2,124
2,461
2,958
3,605
4,105
4,904
5,584
6,410
7,274
8,028
8,362
Total Equity
12.61
15.01
16.17
16.48
17.03
14.06
13.18
14.55
17.18
18.77
18.27
17.19
16.43
16.89
16.74
13.84
13.48
Return on Invested Capital (%)
14.4
16.73
18.2
19
18.99
15.78
14.7
16.59
18.16
19.75
18.65
17.39
17.32
17.11
16.59
13.76
13.62
Return on Capital (%)
17.99
20.9
22.66
23.21
23.74
18.08
15.84
17.35
19.4
20.16
18.82
17.64
17.09
17.2
16.65
13.77
13.64
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
48
79
57
LT Borrowings
- -
- -
- -
LT Finance Leases
20
16
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,016
1,016
1,016
Market Capitalization
24,511
22,754
19,046

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,463
6,875
6,736
Cash, Cash Equivalents & STI
4,019
4,130
3,744
Accounts Receivable, Net
1,472
1,759
1,757
Inventories
757
695
858
Total Current Liabilities
1,092
1,207
1,083
Payables & Accruals
- -
- -
- -
ST Debt
48
79
57
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16%
14.39%
10.37%
Free Cash Flow
-94.27%
-2.36%
37.53%
Net Income, GAAP
15.68%
8.04%
-7.54%
Sales/Revenue/Turnover
8.41%
12.07%
3.75%
Total Cash Common Dividend
27.66%
33.97%
13.11%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,358
1,406
1,382
1,552
5,698
2025
1,511
1,499
- -
1,440
5,911
2026
1,610
1,608
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.26
0.36
0.38
0.12
1.13
2025
0.3
0.4
- -
-0.05
1.05
2026
0.31
0.42
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.32
- -
- -
0.32
2025
- -
0.36
- -
- -
0.36
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jiangsu Nhwa Pharmaceutical Co., Ltd. Jiangsu Nhwa Pharmaceutical Co., Ltd. (002262.SZ) engages primarily in the research, development, production, and sale of central nervous system (CNS) drugs in China. The company offers a portfolio of pharmaceutical products across key categories including anesthetic medicines such as midazolam injections, etomidate fat emulsion injections, and doxapram hydrochloride injections; psychiatric medicines such as risperidone tablets, buspirone hydrochloride tablets, zaleplon capsules, and lithium carbonate sustained-release tablets; neurological medicines such as gabapentin capsules, riluzole tablets, and triazolam tablets; other drugs including naproxen sustained-release capsules and duloxetine HCl; and active pharmaceutical ingredients (APIs) such as fenofibrate and miconazole nitrate. Founded in 1978 and headquartered in Xuzhou, China, the company operates automated production lines for tablets, capsules, water injections, and powder injections, serving markets in anesthesiology, psychiatry, and neurology while maintaining subsidiaries focused on pharmaceutical wholesale, retail, precision CNS diagnostics, and digital health platforms. In recent developments, Jiangsu Nhwa entered a strategic partnership with Teva Pharmaceutical Industries Ltd. in February 2024 to commercialize Austedo (deutetrabenazine) for treating chorea associated with Huntington's disease and tardive dyskinesia in China, enhancing patient access in neuro-psychiatric segments; the company also obtained approval for tapentadol hydrochloride tablets and reported steady revenue growth to RMB 4.47 billion in the first nine months of 2025, driven by high-barrier anesthetic products and pipeline expansions in anesthesia, analgesics, and innovative CNS therapies amid procurement stabilization.